In this cohort of the retrospective study, serum AFP data were produced from multiple agents from different providers, and the positive rates of serum AFP in HCC varied considerably at 84.19% (Roche), 67.35% (Huzhou Shukang), 78.07% (Abbott) and 77.27% (Beckman Coulter), respectively (Table S3). This evidence concerns the gene AFP and hepatocellular carcinoma.